SCHEMBL5490339

SCHEMBL5490339

N#CC(NCc1ccccc1)C1(C=O)CC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADH1B P00325 1/20 0.39
ADH1C P00326 1/20 0.39
ADH1A P07327 1/20 0.39
ADH7 P40394 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.38
SIGMAR1 Q99720 1/20 0.36
MCL1 Q07820 2/20 0.36
ACP3 P15309 3/20 0.35
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
ATM Q13315 2/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
PLIN1 O60240 1/20 0.34
LMNA P02545 1/20 0.34
PLIN5 Q00G26 1/20 0.34
ABHD5 Q8WTS1 1/20 0.34
CTSS P25774 1/20 0.34
KDM4E B2RXH2 2/20 0.33
HPGD P15428 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15898195 0.71 CTSC (0.38) SMN1; SMN2SIGMAR1L3MBTL1LMNACTSS
SCHEMBL8297976 0.71 EPHX2 (0.47) SMN1; SMN2MEN1KMT2AHPGDTSHR
SCHEMBL7862909 0.70 PPID (0.43) SMN1; SMN2MEN1KMT2ATDP1ATM
SCHEMBL5497103 0.70 KDM4E (0.36) SMN1; SMN2SIGMAR1MEN1KMT2AATM
SCHEMBL24581622 0.69 ALDH1A1 (0.34) SMN1; SMN2SIGMAR1MEN1KMT2AL3MBTL1
SCHEMBL19185595 0.68 SIGMAR1 (0.42) SMN1; SMN2SIGMAR1MCL1ACP3MEN1
SCHEMBL19185547 0.68 SIGMAR1 (0.48) ADH1BADH1CADH1AADH7SMN1; SMN2
SCHEMBL24323636 0.66 SIGMAR1 (0.40) SMN1; SMN2SIGMAR1MCL1CTSSKDM4E
SCHEMBL3338932 0.65 SIGMAR1 (0.55) SMN1; SMN2SIGMAR1MCL1MEN1KMT2A
SCHEMBL13266485 0.64 SMN1; SMN2 (0.50) SMN1; SMN2SIGMAR1ACP3MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1310487-B1 PROCESSES FOR PREPARATION OF BICYCLIC COMPOUNDS AND INTERMEDIATES THEREFOR DAIICHI SEIYAKU CO (JP) 2007-01-03 EP disclosed
US-7074837-B2 Processes for preparation of bicyclic compounds and intermediates therefor DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2006-07-11 US disclosed
US-20050272797-A1 Processes for preparation of bicyclic compounds and intermediates therefor DAIICHI PHARMACEUTICAL CO., LTD. 2005-12-08 US disclosed
US-20040019223-A1 Processes for preparation of bicyclic compounds and intermediates therefor DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-01-29 US disclosed
EP-1310487-A1 PROCESSES FOR PREPARATION OF BICYCLIC COMPOUNDS AND INTERMEDIATES THEREFOR DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2003-05-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040019223-A1 Processes for preparation of bicyclic compounds and intermediates therefor DCXR, CYP51A1, WEE1 ADH1B 718/4885ADH1C 2663/4885ADH1A 2699/4885
US-20050272797-A1 Processes for preparation of bicyclic compounds and intermediates therefor DCXR, WEE1, CYP51A1 ADH1B 719/4885ADH1C 2874/4885ADH1A 2883/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.